The Polen 5Perspectives Growth Opportunities Q3 2026 review reports a difficult quarter for the strategy, with the composite portfolio returning -6.2% net of fees. That result compares with a 0.5% gain for the Russell 3000 Growth Index over the same period, leaving the portfolio 6.7 percentage points behind its benchmark.
Performance Gap Widens Against Growth Benchmark
The third-quarter figures, disclosed in Polen Capital’s commentary for the 5Perspectives Growth Opportunities Composite Portfolio, show a sharp divergence between the strategy and the broad growth market. While the Russell 3000 Growth Index managed a modest positive return, the portfolio’s net decline pushed absolute performance into negative territory for the period.
The 6.2% net loss reflects returns after fees, according to the firm’s reporting. The benchmark’s 0.5% return set the relative bar for the quarter, and the portfolio’s shortfall was driven primarily by a handful of holdings and positioning decisions rather than broad-based weakness across every name.
Twist Bioscience, CrowdStrike and Micron Lead Relative Gains
On the positive side, three positions stood out for their contribution to relative performance during the quarter. Twist Bioscience and CrowdStrike were both named among the top relative contributors. Micron Technology also contributed favorably, and notably did so as an underweight position.
The inclusion of an underweight in Micron among the top contributors indicates that the portfolio’s relative standing benefited from holding less of the stock than the benchmark during a period when that positioning helped performance. The same dynamic applied to other relative contributors, where the size of a position rather than only its absolute return shaped the outcome.
Argan, Microsoft and Bloom Energy Detract
The most significant drags on relative performance came from Argan, Microsoft and Bloom Energy. Microsoft’s negative contribution was tied to an underweight position, meaning the portfolio’s relative result was hurt by holding a smaller stake than the benchmark during the quarter.
Argan and Bloom Energy were listed among the most significant detractors without further attribution detail in the summary. Together with the Microsoft underweight, these three names accounted for the largest negative relative effects identified in the quarterly review.
What the Quarter Reveals About Relative Positioning
The attribution for the quarter is a study in how relative performance can diverge from absolute returns. Two of the six named positions—Micron on the positive side and Microsoft on the negative side—are identified explicitly as underweights, showing that the portfolio’s deviation from benchmark weights played a meaningful role in the quarter’s outcome.
For investors reviewing the report, the key takeaway is the scale of the gap: a 6.2% net decline against a 0.5% index gain. The top contributors and detractors named in the commentary provide the clearest available map of where that gap originated during the three-month period.
Quarterly Snapshot
- Portfolio return: -6.2% net of fees
- Benchmark return: 0.5% for the Russell 3000 Growth Index
- Top relative contributors: Twist Bioscience, CrowdStrike, Micron Technology (underweight)
- Most significant relative detractors: Argan, Microsoft (underweight), Bloom Energy
The Q3 2026 review captures a quarter in which the growth strategy’s holdings and weighting decisions produced a marked shortfall versus the Russell 3000 Growth Index. The named contributors and detractors offer a focused view of the positions that shaped that result.